BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Maier-Stocker C, Bitzer M, Malek NP, Plentz RR. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scand J Gastroenterol 2014;49:1480-5. [PMID: 25390691 DOI: 10.3109/00365521.2014.978816] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int 2015;2015:681653. [PMID: 26161408 DOI: 10.1155/2015/681653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Yoneyama H, Takizawa-hashimoto A, Takeuchi O, Watanabe Y, Atsuda K, Asanuma F, Yamada Y, Suzuki Y. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anti-Cancer Drugs 2015;26:90-100. [DOI: 10.1097/cad.0000000000000165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917-4924. [PMID: 28599496 DOI: 10.3892/ol.2017.6061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
5 Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 2017;8:925-35. [PMID: 29299351 DOI: 10.21037/jgo.2017.09.05] [Reference Citation Analysis]
6 Nishiofuku H, Tanaka T, Marugami N, Sho M, Akahori T, Nakajima Y, Kichikawa K. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol 2016;26:1835-42. [PMID: 26385808 DOI: 10.1007/s00330-015-3999-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
7 El-hadaad HA, Wahba HA. Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study. J Gastrointest Canc 2013;44:313-7. [DOI: 10.1007/s12029-013-9495-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
8 Brú A, Bosch R, Céspedes MV, Carmona-Güedes S, Pascual E, Brú I, Souto JC. Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer. Sci Rep 2019;9:2879. [PMID: 30814617 DOI: 10.1038/s41598-019-39805-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]